Reversal of an Acute Parkinsonian Syndrome Associated With Multiple Sclerosis by Application of Weak Electromagnetic Fields

References

• Aita J. F., Bennet D. R., Anderson R. E. Cranial CT appearance of acute multiple sclerosis. Neurology 1978; 28: 251–255
   PubMed Web of Science ®Google Scholar
• Aldegunde M., Miguez I., Veira J. Effects of pinealectomy on regional brain serotonin metabolism. International Journal of Neuroscience 1985; 26: 9–13
   PubMed Web of Science ®Google Scholar
• Anton-Tay F., Diaz J. L., Fernandez-Guardiola A. On the effects of melatonin upon human brain. Its possible therapeutic implications. Life Sciences 1971; 10: 841–850
   Web of Science ®Google Scholar
• Auff E., Birkmayer W., Brucke T., Deecke L., Emich C, Goldenberg G., Hirsch E., Maly J., Muller C., Potzl G., Riederer P., Sofic E., Schnaberth G. Ritanserin in the treatment of tremor-dominant Parkinson's disease: a preliminary study. New Trends in Clinical Neuropharmacology 1987; 1: 149–158
   Google Scholar
• Awerbuch G. I., Sandyk R. Focal dystonia as the presenting manifestation of multiple sclerosis. International Journal of Neuroscience 1992; 62: 273–275
   PubMedGoogle Scholar
• Bachman D. S., Lao-Velez C., Estanol B. Dystonia and choreoathetosis in multiple sclerosis. Archives of Neurology 1976; 33: 590
   PubMedGoogle Scholar
• Barbeau A. Contributions of levodopa therapy to the neuropharmacology of akinesia. Parkinson's disease: rigidity, akinesia, behavior, J. Siegfried. Hans Huber Publishing, Bern 1972; vol. 1: 151–174
   Google Scholar
• Barolin G. W., Hornykiewicz O. Zur diagnostischen Wertigkeit der Homovanillinsaeure im Liquor cerebrospinalis. Wien Klinische Wochenschrift 1967; 79: 815–818
   PubMedGoogle Scholar
• Bawin S. M., Adey W. R. Sensitivity of calcium binding in cerebral tissue to weak environmental electric fields oscillating at low frequency. Proceedings of the National Academy of Sciences, USA 1976; 73: 1999–2003
   PubMed Web of Science ®Google Scholar
• Berger J. R., Sheremata W. A., Melamed E. Paroxysmal dystonia as the initial manifestation of multiple sclerosis. Archives of Neurology 1984; 41: 747–750
   PubMedGoogle Scholar
• Bernheimer H., Birkmayer W., Hornykiewicz O. Verteilung des 5-hydroxytryptamins (Serotonin) in Gehirn des Menschen und sein Verhalten bein Patienten mit Parkinson Syndrome. Klinische Wochenschrift 1961; 39: 1056–1059
   PubMedGoogle Scholar
• Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndrome of Parkinson and Huntington. Clinical morphological and neurochemical correlations. Journal of the Neurological Sciences 1973; 20: 415–455
   PubMed Web of Science ®Google Scholar
• Bigne J., Lapuerta L. Sobre la influencia de las emociones en el sindrome parkinsoniano. Revista Clinica Espanola 1961; 83: 289–291
   PubMedGoogle Scholar
• Blackman C. F. Stimulation of brain tissue in vitro by extremely low frequency, low intensity, sinusoidal electromagnetic fields. Electromagnetic fields and neurobehavioral function, M. E. O'Connor, R. H. Lovely. Alan R. Liss, New York 1988
   Google Scholar
• Boman K. Effect of emotional stress on spasticity and rigidity. Scandinavian Journal of Clinical and Laboratory Investigation 1969; 23: 63, (suppl. 108)
   Google Scholar
• Bradbury A. J., Kelly M. E., Smith J. A. Melatonin action in the mid-brain can regulate dopamine function both behaviourally and biochemically. The pineal gland: endocrine aspects, G. M. Brown, S. D. Wainwright. Pergamon Press, Oxford 1985; 327–332
   Google Scholar
• Brickner R. M., Simons D. J. Emotional stress in relation to attacks of multiple sclerosis. Association for Research in Nervous Disorders Proceedings 1950; 28: 143–149
   PubMedGoogle Scholar
• Brozoski T. J., Brown R. M., Rosvold H. E., Goldman P. S. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science 1979; 205: 929–932
   PubMed Web of Science ®Google Scholar
• Burton S., Daya S., Potgieter B. Melatonin modulates apomorphine-induced rotational behaviour. Experientia 1991; 47: 466–469
   PubMedGoogle Scholar
• Cantello R., Aguggia M., Gilli M., Delsedime M., Chiardo Cutin I., Riccio A., Mutani R. Major depression in Parkinson's disease and the mood response to intravenous methylphenidate: possible role of the “hedonic” dopamine synapse. Journal of Neurology Neurosurgery and Psychiatry 1989; 52: 724–731
   PubMed Web of Science ®Google Scholar
• Cardinali D. P. Changes in hypothalamic neurotransmitter uptake following pinealectomy, superior cervical ganglionectomy or melatonin administration to rats. Neuroendocrinology 1975; 19: 91–95
   PubMed Web of Science ®Google Scholar
• Cardinali D. P., Vacas M. l., Boyer E. E. Specific binding of melatonin in bovine brain. Endocrinology 1979; 105: 437–441
   PubMed Web of Science ®Google Scholar
• Chase T. N., Ng L. K. Y. Probenecid test in Parkinson's disease. lancet 1971; 2: 1265–1266
   PubMedGoogle Scholar
• Chelmicka-Schorr E., Arnason B. G. Nervous system-immune system interactions and their role in multiple sclerosis. Annals of Neurology 1994; 36: S29–S32, (suppl)
   Google Scholar
• Claveria L. E., Curzon G., Harrison M. J. G., Kantamaneni B. D. Amine metabolites in the cerebrospinal fluid of patients with disseminated sclerosis. Journal of Neurology, Neurosurgery and Psychiatry 1974; 37: 715–718
   PubMed Web of Science ®Google Scholar
• Cotzias G. C., Tang L. C., Miller S. T., Ginos J. Z. Melatonin and abnormal movement induced by L-dopa in mice. Science 1971; 173: 450–452
   PubMed Web of Science ®Google Scholar
• Davidson D., Pullar I. A., Mawdsley C., Kinloch N., Yates C. M. Monoamine metabolites in cerebrospinal fluid in multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry 1977a; 40: 741–745
   PubMed Web of Science ®Google Scholar
• Davidson D. L. W., Yates C. M., Mawdsley C., Pullar I. A., Wilson H. CSF studies on the relationship between dopamine and 5-hydroxytryptamine in Parkinsonism and other movement disorders. Journal of Neurology Neurosurgery and Psychiatry 1977b; 40: 1136–1141
   PubMed Web of Science ®Google Scholar
• Dray A. Serotonin in the basal ganglia: functions and interactions with other neuronal pathways. Journal of Physiology, (Paris) 1981; 77: 393–403
   PubMedGoogle Scholar
• Dubocovich M. L. Melatonin is a potent modulator of dopamine release in the retina. Nature 1983; 306: 782–784
   PubMed Web of Science ®Google Scholar
• Durif F., Vidailhet M., Bonnet A. M., Blin J., Agid Y. Levodopa-induced dyskinesias are imporved by fluoxetine. Neurology 1995; 45: 1855–1858
   PubMed Web of Science ®Google Scholar
• Fahn S., Libsch L. R., Cutler R. W. Monoamines in the human neostriatum: Topographic distribution in normals in Parkinson's disease and their role in akinesia, rigidity, chorea and tremor. Journal of Neurological Sciences 1971; 14: 427–455
   PubMed Web of Science ®Google Scholar
• Fibiger H. C. The neurobiological substrates of depression in Parkinson's disease: a hypothesis. Canadian Journal of Neurological Sciences 1984; 11: 105–107
   PubMed Web of Science ®Google Scholar
• Fog T., Linneman F. The course of multiple sclerosis. Acta Neurologica Scandinavica 1970; 47: 1–175, (suppl)
   Google Scholar
• Gilbert J. J., Sadler M. Unsuspected multiple sclerosis. Archives of Neurology 1983; 40: 533–536
   PubMedGoogle Scholar
• Gottfries C. G., Gottfries I., Roos B. E. Homovanillic acid and 5-hydroxyindoleacetic acid in the cerebrospinal fluid of patients with senile dementia, presenile dementia and parkinsonism. Journal of Neurochemistry 1969; 16: 1341–1345
   PubMed Web of Science ®Google Scholar
• Gottfries C. G., Gottfries I., Johansson B., Olsson R., Persson T., Roos B. E., Sjostrom R. Acid monoamine metabolites in human cerebrospinal fluid and their relations to age and sex. Neuropharmacology 1971; 10: 665–672
   PubMedGoogle Scholar
• Gumpert J., Sharpe D., Curzon G. Amine metabolites in the cerebrospinal fluid in Parkinson's disease and the response to levodopa. Journal of Neurological Sciences 1973; 19: 1–12
   PubMed Web of Science ®Google Scholar
• Herman M. E. Cas de sclerose en plaques avec mouvements involontaires a caratere extrapyramidal et avec paraplegie flasque. Revue Neurologique (Paris) 1929; 51: 290–291
   Google Scholar
• Hong J. S., Tilson H. A., Uphouse L. L., Gerhart J., Wilson W. E. Effects of chlordecone exposure on brain neurotransmitters: possible involvement of the serotonin system in chlordecone elicited tremor. Toxicology and Applied Pharmacology 1984; 73: 336–344
   PubMed Web of Science ®Google Scholar
• Hornykiewicz O. Dopamine (3-hydroxytyramine) and brain function. Pharmacological Reviews 1966; 18: 925–964
   PubMed Web of Science ®Google Scholar
• Ishizaki F., Nishikawa S. Relation of blood serotonin and benzylamine oxidase to clinical symptoms and prognosis in Parkinson's disease. European Neurology 1988; 28: 291–294
   PubMed Web of Science ®Google Scholar
• Jaffe R. A., Laszewski B. L., Carr D. B., Phillips R. D. Chronic exposure to a 60-Hz electric field: effects on synaptic transmission and peripheral nerve function in the rat. Bioelectromagnetics 1980; 1: 131–147
   PubMedGoogle Scholar
• Javoy-Agid F., Agid Y. Is the mesocortical dopaminergic system involved in Parkinson's disease?. Neurology 1980; 30: 1326–1330
   PubMed Web of Science ®Google Scholar
• Johansson B., Roos B. E. 5-hydroxyindoleacetic acid and homovanillic acid levels in the cerebrospinal fluid of healthy volunteers and patients with Parkinson's sundrome. Life Sciences 1967; 6: 1446–1454
   Google Scholar
• Johansson B., Ross B. E. 5-hydroxyindoleacetic acid and homovanillic acid in CSF of patients with neurological disease. European Neurology 1977; 11: 37–45
   Web of Science ®Google Scholar
• Koller W. C. Classification of parkinsonism. Handbook ofparkinson's disease, W. C. Roller. Marcel Dekker, New York 1987; 51–80
   Google Scholar
• Kopp N., Claustrat B., Tappaz M. Evidence for the presence of melatonin in the human brain. Neuroscience Letters 1980; 19: 237–242
   PubMed Web of Science ®Google Scholar
• Kostic V. S., Djuricic B. M., Covickovic-Sternic N., Bumbasirevic L., Nikolic M., Mrsulja B. B. Depression and Parkinson's disease: possible role of serotonergic mechanisms. Journal of Neurology 1987; 234: 94–96
   PubMed Web of Science ®Google Scholar
• Kovacs G. L., Gayari I., Telegdy G., Lissak K. Effect of melatonin and pinealectomy on avoidance and exploratory activity in the rat. Physiology and Behavior 1974; 13: 349–355
   PubMed Web of Science ®Google Scholar
• Laudon M., Nir I., Zisapel N. Melatonin receptors in discrete brain areas of the male rat. Impact of aging on density and on circadian rhythmicity. Neuroendocrinology 1988; 48: 577–583
   PubMed Web of Science ®Google Scholar
• Lezak M. D. Neuropsychological assessment, second Edition. Oxford University Press, New York 1983; 405–406
   Google Scholar
• Li D. K. B., Mayo J., Fache S., Robertson W., Lastrukoff L. F., Oger J., Paty D. W. Lack of correlation between clinical manifestations and lesions of MS as seen by NMR. Neurology 1984; 34: 136, (suppl)
   PubMed Web of Science ®Google Scholar
• Lumsden C. E. The neuropathology of multiple sclerosis. Handbook of clinical neurology, P. J. Vinken, G. W. Bruyn. North Holland, Amsterdam 1970; vol. 9: 217–309
   Google Scholar
• MackKay R. P., Hirano A. Forms of benign multiple sclerosis: report of two clinicaly silent cases discovered at autopsy. Archives of Neurology 1967; 17: 588–600
   PubMedGoogle Scholar
• Mao C. C., Gancher S. T., Herndon R. M. Movement disorders in multiple sclerosis. Movement Disorders 1988; 3: 109–116
   PubMedGoogle Scholar
• Markianos M., Sfagos C. Altered serotonin uptake kinetics in multiple sclerosis. Journal ofNeurology 1988; 235: 236–237
   Google Scholar
• Mayeux R., Stern Y., Rosen J., Leventhal J. Depression, intellectual impairment and Parkinson's disease. Neurology 1981; 31: 645–650
   PubMed Web of Science ®Google Scholar
• Mayeux R., Stern Y., Cote L., Williams J. B. W. Altered serotonin metabolism in depressed patients with Parkinson's disease. Neurology 1984; 34: 642–646
   PubMed Web of Science ®Google Scholar
• Mayeux R., Stern Y., Williams J. B. W., Cote L., Frantz A., Dyrenfurth I. Clinical and biochemical features of depression in Parkinson's disease. American Journal of Psychiatry 1986; 143: 756–759
   PubMed Web of Science ®Google Scholar
• Mayeux R., Stern Y., Sano M., Williams J. B. W., Cote L. J. The relationship of serotonin to depression in Parkinson's disease. Movement Disorders 1988; 3: 237–244
   PubMed Web of Science ®Google Scholar
• McAIpine D., Lumsden C. E., Acheson E. D. Multiple sclerosis: a reappraisel. Williams and Wilkins, Baltimore 1972; 177–178
   Google Scholar
• McCance-Katz E. F., Marek K. L., Price L. H. Serotonergic dysfunction in depression associated with Parkinson's disease. Neurology 1992; 42: 1813–1814
   PubMed Web of Science ®Google Scholar
• Meerwaldt J. D. Treatment of hypokinetic rigid syndrome with fluvoxamine maleate. Lancet 1986; 2: 977–978
   Google Scholar
• Miguez J. M., Martin F., Aldegunde M. Differential effects of pinealectomy on amygdala and hippocampus serotonin metabolism. Journal of Pineal Research 1991a; 10: 100–103
   PubMed Web of Science ®Google Scholar
• Miguez J. M., Martin F., Aldegunde M. Long-term pinealectomy alters hypothalamic serotonin metabolism in the rat. Journal of Pineal Research 1991b; 11: 75–79
   PubMed Web of Science ®Google Scholar
• Miguez J. M., Martin F. J., Aldegunde M. Effects of single doses and daily melatonin treatments on serotonin metabolism in rat brain regions. Journal of Pineal Research 1994; 17: 170–176
   PubMed Web of Science ®Google Scholar
• Miller J. D., Speciale S. G., McMillen B. A., German D. C. Naloxone antagonism of stress-induced augmentation of frontal cortex dopamine metabolism. European Journal of Pharmacology 1984; 98: 437–439
   PubMed Web of Science ®Google Scholar
• Monaco F., Fumero S., Mondino A., Mutani R. Plasma and cerebrospinal fluid tryptophan in multiple sclerosis and degenerative diseases. Journal ofNeurology, Neurosurgery and Psychiatry 1979; 42: 640–641
   PubMed Web of Science ®Google Scholar
• Mouren P., Tatossian A., Toga M. Etude critique du syndrome hemiballistique. Encephale 1966; 53: 212–274
   Google Scholar
• Namerow N. S., Thompson L. B. Plaques, symptoms, and the remitting course of multiple sclerosis. Neurology 1969; 19: 765–774
   PubMedGoogle Scholar
• Niles L. P., Wong Y. W., Mishra R. K., Brown G. M. Melatonin receptors in brain. European Journal of Pharmacology 1979; 55: 219–220
   PubMed Web of Science ®Google Scholar
• Obeso J. A., Martinez-Lage J. M. Relapsing Parkinson's disease. British Medical Journal 1984; 288: 368
   PubMedGoogle Scholar
• Ogawa N., Yamamoto M. Neurotransmitters and their receptors in parkinsonism. Current problems in treatment of Parkinson's disease, Y. Kuroiwa, Y. Toyokura. DMW, Japan 1985; 23–32
   Google Scholar
• Purves S. Paralysis agitans; with an account of a new symptom. Lancet 1898; 2: 1258–1260
   Google Scholar
• Raine C. S. Demyelinating diseases. Textbook of neuropathology, R. L. Davis, D. M. Robertson. Williams and Wilkins, Baltimone 1985; 468–547
   Google Scholar
• Riederer P., Wuketich S. Time course of nigrostriatal degeneration in Parkinson's disease. Journal of Neural Transmission 1976; 38: 277–301
   PubMed Web of Science ®Google Scholar
• Riley D., Lang A. E. Hemiballism in multiple sclerosis. Movement Disorders 1988; 3: 88–94
   PubMed Web of Science ®Google Scholar
• Sandyk R. Weak magnetic fields as a novel therapeutic modality in Parkinson's disease. International Journal of Neuroscience 1992a; 66: 1–15
   PubMed Web of Science ®Google Scholar
• Sandyk R. Magnetic fields in the therapy of parkinsonism. International Journal of Neuroscience 1992b; 66: 209–235
   PubMed Web of Science ®Google Scholar
• Sandyk R. Weak magnetic fields in the treatment of Parkinson's disease with the “on-off” phenomenon. International Journal of Neuroscience 1992c; 66: 97–106
   PubMed Web of Science ®Google Scholar
• Sandyk R. The pineal gland and multiple sclerosis. (Editorial). International Journal of Neuroscience 1992d; 63: 206–215
   Web of Science ®Google Scholar
• Sandyk R. Demyelination as an epiphenomenon in multiple sclerosis. International Journal of Neuroscience 1993; 72: 141–148
   PubMedGoogle Scholar
• Sandyk R. A drug naive Parkinsonian patient successfully treated with electromagnetic fields. International Journal of Neuroscience 1994; 79: 99–110
   PubMed Web of Science ®Google Scholar
• Sandyk R. Improvement of body image perception in Parkinson's disease by treatment with weak electromagnetic fields. International Journal of Neuroscience 1995; 82: 269–283
   PubMed Web of Science ®Google Scholar
• Sandyk R. Freezing of gait in Parkinson's disease is improved by treatment with weak electromagnetic fields. International Journal of Neuroscience., (in press)
   Google Scholar
• Sandyk R., Fisher H. L-tryptophan supplementation in Parkinson's disease. International Journal of Neuroscience 1989a; 45: 215–219
   PubMed Web of Science ®Google Scholar
• Sandyk R., Fisher H. Increased incidence and severity of neuroleptic-induced movement disorder in pinealectomized rats. International Journal of Neuroscience 1989b; 48: 303–308
   PubMed Web of Science ®Google Scholar
• Sandyk R., Derpapas K. Further observations on the unique efficacy of picotesla magnetic fields in Parkinson's disease. International Journal of Neuroscience 1993; 69: 167–183
   PubMedGoogle Scholar
• Sandyk R., lacono R. P. Reversal of visual neglect in Parkinson's disease by treatment with picotesla range magnetic fields. International Journal of Neuroscience 1993; 73: 93–107
   PubMedGoogle Scholar
• Sandyk R., Anninos P. A., Tsagas N., Derpapas K. Magnetic fields in the treatment of Parkinson's disease. International Journal of Neuroscience 1992; 63: 141–150
   PubMed Web of Science ®Google Scholar
• Sarkari N. B. S. Involuntary movements in multiple sclerosis. British Medical Journal 1968; 2: 738–740
   PubMedGoogle Scholar
• Schwab R. S., Zeiper I. Effects of mood, motivation, stress and alertness on the performance in Parkinson's disease. Psychiatria et Neurologia 1965; 150: 345–357
   PubMedGoogle Scholar
• Seguela P., Geffard M., Chauveau J., Muyard J. P., Biziere K., Le Moal M. Selective increase of melatonin content in pineal gland and nucleus accumbens after peripheral injection of Des-Tyr'-gamma-en-dorphin in the rat. Neuroscience Letters 1982; 10: S442
   Google Scholar
• Semm P. Neurobiological investigations on the magnetic sensitivity of the pineal gland in rodents and pigeons. Comparative Biochemistry and Physiology 1983; 76A: 683–689
   Web of Science ®Google Scholar
• Semm P., Vollrath L. Electrical responses of homing pigeon and guinea pig Purkinje cells to pineal indoleamines applied by microelectrophoresis. Journal of Comparative Physiology 1984; 154: 675–681
   Web of Science ®Google Scholar
• Semm P., Schneider T., Vollrath L. Effects of an earth-strengh magnetic field on electrical activity of pineal cells. Nature 1980; 288: 607–608
   PubMed Web of Science ®Google Scholar
• Sergott R. C., Brown M. J., Silberberger D. H. Remyelination follows antibody-induced central nervous system demyelination. Annals of Neurology 1986; 20: 94–98
   PubMed Web of Science ®Google Scholar
• Shibasaki H., Kuroiwa Y. Painful tonic seizure in multiple sclerosis. Archives of Neurology 1974; 30: 47–51
   PubMedGoogle Scholar
• Sonninen V., Riekkinen P., Rinne U. K. Acid monoamine metabolites in cerebrospinal fluid in multiple sclerosis. Neurology 1973; 23: 760–763
   PubMed Web of Science ®Google Scholar
• Sugden D., Morris R. D. Changes in regional brain levels of tryptophan, 5-hydroxytryptamine, 5-hy-droxyindoleacetic acid, dopamine and noradrenaline after pinealectomy in the rat. Journal ofNeurochemistry 1979; 32: 1593–1595
   PubMed Web of Science ®Google Scholar
• Tabaddor K., Wolfson L. I., Sharpless N. S. Ventricular fluid homovanillic acid and 5-hydroxyin-doleacetic acid concentrations in patients with movement disorders. Neurology 1978; 28: 1249–1253
   PubMed Web of Science ®Google Scholar
• Taff I., Sabato U. C., Lehrer G. Choreoathetosis in multiple sclerosis. Clinical Neurology and Neurosurgery 1985; 87: 41–43
   PubMed Web of Science ®Google Scholar
• Thiery E., de Reuck J. Monoballism and multiple sclerosis. Acta Neurologica Belgica 1974; 74: 241–249
   PubMedGoogle Scholar
• Thierry A. M., Tassin J. P., Blanc G., Glowinski J. Selective activation of the mesocortical DA system by stress. Nature 1976; 263: 242–244
   PubMed Web of Science ®Google Scholar
• Tohgi H., Abe T., Takahashi S., Takahashi J., Hamato H. Alterations in the concentration of serotonergic and dopaminergic substances in the cerebrospinal fluid of patients with Parkinson's disease and their changes after L-dopa administration. Neuroscience Letters 1993; 159: 135–138
   PubMed Web of Science ®Google Scholar
• Tranchant C., Bhatia K. P., Marsden C. D. Movement disorders in multiple sclerosis. Movement Disorders 1995; 10: 418–423
   PubMed Web of Science ®Google Scholar
• Vieregge P., Klostermann W. Parkinsonism in multiple sclerosis. Movement Disorders 1992; 7: 380–386
   PubMedGoogle Scholar
• Vitte P. A., Harthe C., Lestage P., Claustrat B., Bobillier P. Plasma, CSF and brain distribution of C14-melatonin in rat: a biochemical and autoradiographic study. Journal of Pineal Research 1988; 5: 437–453
   PubMed Web of Science ®Google Scholar
• Welker H. A., Semm P., Willig R. P., Commentz J. C., Wiltschko W., Vollrath L. Effects of an artificial magnetic field on serotonin N-acetyltransferase activity and melatonin content of the rat pineal gland. Experimental Brain Research 1983; 50: 426–432
   PubMed Web of Science ®Google Scholar
• Wilson B. W., Chess E. K., Anderson L. E. 60-Hz electric-field effects on pineal melatonin rhythms: time course for onset and recovery. Bioelectromagnetics 1986; 7: 239–242
   PubMed Web of Science ®Google Scholar
• Wilson B. W., Stevens R. G., Anderson L. E. Neuroendocrine mediated effects of electromagnetic field exposure: possible role of the pineal gland. Life Sciences 1989; 45: 1319–1332
   PubMed Web of Science ®Google Scholar
• Young I. R., Hall A. S., Pallis C. A. Nuclear magnetic resonance imaging of the brain in multiple sclerosis. Lancet 1981; 2: 1063–1066
   PubMed Web of Science ®Google Scholar
• Zigmond M. J., Acheson A. L., Stachowiak M. K., Strickerm E. M. Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism. Archives of Neurology 1984; 41: 856–861
   PubMedGoogle Scholar
• Zisapel N., Laudon M. Inhibition by melatonin of dopamine release from rat hypothalamus: regulation of calcium entry. Brain Research 1983; 272: 378–381
   PubMed Web of Science ®Google Scholar